to chronic disease
Our conviction is that our active immunotherapies have the potential to prevent chronic disease. We are inspired by the impact that vaccinations had in the field of infectious disease, ultimately saving millions of lives and billions of dollars otherwise associated with treatment of symptoms.
In the Western world, neurodegenerative diseases such as Alzheimer’s, Parkinson’s and cardiometabolic disease such as atherosclerosis are among the leading causes of death and are associated with crippling direct cost of care and indirect cost due to loss of productivity to society.
We are curious about the pathways leading to these diseases. We follow the causative cascade and aim to intervene where the pathology starts. This by definition takes us to question the timing of intervention, and posing the question whether intervening when the patient becomes symptomatic might already be too late. Our active immunotherapies stimulate the human body to use its own immune system. They induce a specific, substantial and long lasting immune response whereby the generated antibodies target the proteins believed to be the cause of the disease. The long lasting nature of the immune response that our products induce is our key advantage.
We are struck by the idea that a human immune system might be triggered to articulate an immune response specific to pathological forms of protein that naturally occur in humans. Wouldn’t that in effect augment or delay use of drugs? Could in effect the human body function as a bioreactor that expresses its own very specific response to a pathological process? If this was true in effect our own bodies produce our own personalized drugs.
We believe that this could present a solution with overwhelming economic benefits to society for long term management of civilization illnesses.